Ou Peter, Gear Kim, Rahnama Fahimeh, Thomas Stephen, Nagappan Radhika, Kee Dennis, Waldvogel-Thurlow Sharon, Jain Ravi, McIvor Nick, Izzard Mark, Douglas Richard
Department of Surgery, The University of Auckland, Auckland, New Zealand.
Department of Oto-rhinolaryngology, Head and Neck Surgery, Auckland District Health Board, Auckland, New Zealand.
ANZ J Surg. 2018 Apr;88(4):E278-E283. doi: 10.1111/ans.13759. Epub 2016 Sep 20.
Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinomas (OPSCC) are clinically, epidemiologically and prognostically distinct from other OPSCCs. The incidence of HPV-related OPSCCs has increased significantly worldwide over the past few decades. However, no studies of OPSCC with direct molecular HPV testing has been conducted in New Zealand.
To estimate the proportion of OPSCCs attributable to HPV infections in a New Zealand population with a validated HPV testing algorithm.
HPV-status was determined by p16 immunohistochemistry and polymerase chain reaction (PCR) of both L1 and E6/7 genes on 55 OPSCCs diagnosed in 2010 and 2011 in Central and South Auckland. Baseline and survival analyses were performed according to HPV status.
Forty-one (75%) of OPSCC tumours had HPV infections. There was 98% concordance between p16 immunohistochemistry and real-time E6/E7 PCR. After a median follow-up period of 2.6 years, patients with OPSCC of HPV aetiology had more favourable outcomes compared to patients with HPV-negative OPSCC (hazard ratio 0.14, P = 0.02) after adjustment for other variables.
This study highlights the significant role that HPV plays in the aetiology of OPSCC in New Zealand, and confirms the high rate of accuracy of p16 immunostaining.
人乳头瘤病毒(HPV)相关的口咽鳞状细胞癌(OPSCC)在临床、流行病学和预后方面与其他OPSCC不同。在过去几十年中,全球范围内HPV相关OPSCC的发病率显著增加。然而,新西兰尚未开展过直接进行分子HPV检测的OPSCC研究。
使用经过验证的HPV检测算法,估计新西兰人群中HPV感染所致OPSCC的比例。
对2010年和2011年在奥克兰中部和南部诊断的55例OPSCC进行p16免疫组化以及L1和E6/7基因的聚合酶链反应(PCR),以确定HPV状态。根据HPV状态进行基线和生存分析。
41例(75%)OPSCC肿瘤存在HPV感染。p16免疫组化与实时E6/E7 PCR之间的一致性为98%。在中位随访期2.6年后,在对其他变量进行调整后,HPV病因的OPSCC患者比HPV阴性的OPSCC患者有更有利的预后(风险比0.14,P = 0.02)。
本研究突出了HPV在新西兰OPSCC病因中所起的重要作用,并证实了p16免疫染色的高准确率。